| scholarly article | Q13442814 |
| P2093 | author name string | Mario Habek | |
| Ivan Adamec | |||
| Ivo Lušić | |||
| Nataša Klepac | |||
| Eduard Margetić | |||
| Anabella Karla Barušić | |||
| Ivo Bach | |||
| P2860 | cites work | Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease. | Q54791937 |
| Prevalence of repetitive and reward-seeking behaviors in Parkinson disease | Q57083761 | ||
| Prospective prevalence of pathologic gambling and medication association in Parkinson disease | Q57083763 | ||
| Development of dyskinesias in a 5-year trial of ropinirole andL-dopa | Q57088847 | ||
| Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease | Q57629146 | ||
| A heterozygous effect for PINK1 mutations in Parkinson's disease? | Q58617948 | ||
| Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease | Q62128619 | ||
| Neurotrophic factors in Alzheimer's and Parkinson's disease brain | Q64768197 | ||
| Risk factors for progression in Parkinson's disease | Q67973248 | ||
| Young onset Parkinson's disease | Q68843339 | ||
| Respiratory dyskinesia in Parkinson's disease | Q70007074 | ||
| Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset | Q70529523 | ||
| Early onset Parkinson's disease: are juvenile- and young-onset different? | Q71661544 | ||
| Old-onset Parkinson's disease compared with young-onset disease: clinical differences and similarities | Q72087068 | ||
| Long-term results of bilateral pallidal stimulation in Parkinson's disease | Q80153092 | ||
| Potential therapeutic targets for Parkinson's disease | Q80892733 | ||
| Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients | Q81235528 | ||
| Mutation analysis of Parkin, PINK1 and DJ-1 genes in Chinese patients with sporadic early onset parkinsonism | Q82852102 | ||
| Motor features and response to oral levodopa in patients with Parkinson's disease under continuous dopaminergic infusion or deep brain stimulation | Q84284466 | ||
| Prevalence of parkinsonian signs and associated mortality in a community population of older people | Q51047766 | ||
| Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. | Q53532682 | ||
| Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. | Q53958979 | ||
| The effectiveness of exercise interventions for people with Parkinson's disease: A systematic review and meta-analysis | Q22252884 | ||
| LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool | Q24292798 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients | Q24561822 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| Transcranial magnetic resonance imaging-guided focused ultrasound: noninvasive central lateral thalamotomy for chronic neuropathic pain | Q28256330 | ||
| Parkinsonism: onset, progression, and mortality | Q28259134 | ||
| Neurotrophic factors as a therapeutic target for Parkinson's disease | Q28273071 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 | ||
| Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease | Q28740551 | ||
| Genomewide association study for onset age in Parkinson disease | Q29417034 | ||
| The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study | Q30440660 | ||
| MR-guided adaptive focusing of therapeutic ultrasound beams in the human head | Q30458729 | ||
| R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. | Q30483115 | ||
| Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London | Q30490116 | ||
| Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker | Q33233370 | ||
| Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. | Q33594388 | ||
| Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease | Q33602588 | ||
| The effect of age of disease onset on neuropsychological performance in Parkinson's disease | Q33627343 | ||
| Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion | Q33733575 | ||
| Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? | Q33733822 | ||
| L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. | Q33736399 | ||
| Treatment of Parkinson's disease | Q34058609 | ||
| A comparison of clinical and pathological features of young- and old-onset Parkinson's disease | Q34178160 | ||
| Regulation of brain function by exercise | Q34198682 | ||
| Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. | Q42470896 | ||
| High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases | Q42547326 | ||
| Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. | Q43755224 | ||
| Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial | Q43797815 | ||
| Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease | Q44060158 | ||
| Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial | Q44463354 | ||
| Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study | Q44499883 | ||
| Young-onset Parkinson's disease revisited--clinical features, natural history, and mortality | Q44667840 | ||
| Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease | Q44769508 | ||
| Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group | Q44801417 | ||
| Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease | Q44858279 | ||
| A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa | Q45087241 | ||
| Subthalamic nucleus deep brain stimulation outcome in young onset Parkinson's disease: a role for age at disease onset? | Q45156822 | ||
| Age of Parkinson's disease onset as a predictor for the development of dyskinesia | Q46207050 | ||
| Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease | Q46433073 | ||
| Assessing the prevalence of PINK1 genetic variants in South African patients diagnosed with early- and late-onset Parkinson's disease | Q46683977 | ||
| Haplotype analysis of the engrailed-2 gene in young-onset Parkinson's disease | Q46768641 | ||
| Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa | Q46982728 | ||
| Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? | Q48192076 | ||
| Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial | Q48345455 | ||
| Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life | Q48401377 | ||
| Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease | Q48405890 | ||
| A randomized trial of deep-brain stimulation for Parkinson's disease | Q48433139 | ||
| Prevalence of non-motor symptoms in young-onset versus late-onset Parkinson's disease | Q48640356 | ||
| Role of DaTSCAN and clinical diagnosis in Parkinson disease | Q48665921 | ||
| Quality of life in young- compared with late-onset Parkinson's disease | Q48669290 | ||
| High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease | Q48672278 | ||
| Subthalamic nucleus vs globus pallidus interna deep brain stimulation, the rematch: will pallidal deep brain stimulation make a triumphant return? | Q48932622 | ||
| Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders | Q49155863 | ||
| MR-guided focused ultrasound for brain ablation and blood-brain barrier disruption | Q50246532 | ||
| ??? | Q64768794 | ||
| ??? | Q64818918 | ||
| Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity | Q34201593 | ||
| Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. | Q34416128 | ||
| Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease | Q34466869 | ||
| Diagnostic criteria for Parkinson disease | Q34489839 | ||
| Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes | Q34554855 | ||
| Neuroprotection and dopamine agonists | Q34574592 | ||
| Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial | Q34649706 | ||
| Potential of transdermal drug delivery in Parkinson's disease | Q34808049 | ||
| Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis | Q35058315 | ||
| Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study | Q35525896 | ||
| Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. | Q35560472 | ||
| Long-term motor effect of unilateral pallidal stimulation in 26 patients with advanced Parkinson disease | Q35563677 | ||
| Association of dopamine agonist use with impulse control disorders in Parkinson disease | Q35567194 | ||
| Criteria for diagnosing Parkinson's disease | Q35753854 | ||
| The relevance of iron in the pathogenesis of Parkinson's disease. | Q35754511 | ||
| Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature | Q36140767 | ||
| Cell therapy for Parkinson's disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease | Q36660994 | ||
| Young onset Parkinson's disease. Practical management of medical issues | Q36931239 | ||
| Beating a dead horse: dopamine and Parkinson disease | Q36978681 | ||
| Genetics of Parkinson disease | Q37037053 | ||
| The treatment of movement disorders by deep brain stimulation | Q37047100 | ||
| Future directions in the treatment of Parkinson's disease | Q37050653 | ||
| Recent advances in cell-based therapy for Parkinson disease. | Q37110252 | ||
| Young-onset Parkinson's disease: a clinical review | Q37634827 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease | Q37948713 | ||
| Vaccination for Parkinson's disease | Q37968018 | ||
| New agents promote neuroprotection in Parkinson's disease models | Q38000756 | ||
| Emerging therapies for Parkinson's disease | Q38024685 | ||
| Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. | Q38070888 | ||
| Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway | Q38267597 | ||
| Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease | Q38381821 | ||
| Epidemiology of Parkinson's disease in Finland | Q39225650 | ||
| Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study | Q39360937 | ||
| Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient | Q39434658 | ||
| Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease | Q40197232 | ||
| Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. | Q40874496 | ||
| Management of individuals with Parkinson's disease: rationale and case studies | Q41954218 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 53-62 | |
| P577 | publication date | 2013-10-04 | |
| P1433 | published in | Degenerative neurological and neuromuscular disease | Q27724416 |
| P1476 | title | An update on the management of young-onset Parkinson's disease | |
| P478 | volume | 2 |
Search more.